J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.
Paolo Strati,Koichi Takahashi,Christine B. Peterson,Michael J. Keating,Philip A. Thompson,Naval Daver,Nitin Jain,Jan A. Burger,Zeev Estrov,Susan O'Brien,Hagop M. Kantarjian,William G. Wierda,P. Andrew Futreal,Alessandra Ferrajoli +13 more
TL;DR: Evaluating how clinical and biological factors correlate with outcome in patients with treatment-naive and relapsed chronic lymphocytic leukemia treated with lenalidomide and rituximab found a trend for association between mutations in the NOTCH pathway and shorter PFS was observed.
Journal ArticleDOI
A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia.
Shilpa Paul,Nitin Jain,Alessandra Ferrajoli,Susan O'Brien,Jan A. Burger,Michael J. Keating,William G. Wierda +6 more
TL;DR: Clinically, sIL2R is very helpful in differentiating HLH from mimickers such as sepsis, liver disease, haemolysis and transfusion and much like ferritin, it is a dynamic marker of disease activity and can facilitate monitoring of response to treatment.
Journal ArticleDOI
Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL/SLL (RESONATE-2, PCYC-1115-CA).
Jan A. Burger,Paolo Ghia,Aaron Polliack,Constantine S. Tam,Deepali Suri,Fong Clow,Silvija Kraljevic,Danelle F. James,Thomas J. Kipps +8 more
TL;DR: Findings support a phase III study of ibrutinib in older patients with treatment-naive CLL/SLL, and a randomized, multicenter, open label Ph 3 study comparing safety and efficacy of Ibrut inib vs. chlorambucil in TN patients aged >= 65 yrs with CLL /SLL.
Journal ArticleDOI
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies
Jan A. Burger,Paula Cramer,Paul M. Barr,Marie Sarah Dilhuydy,Anthony R. Mato,John C. Byrd,Stephen Chang,Thorsten Graef,Tony Lin,Alessandra Tedeschi +9 more
TL;DR: Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy and prognostic significance of X-ray cross-complementing group 1 T77C polymorphism in resected non-small cell lung cancer is studied.
Journal ArticleDOI
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
Yasmin Abaza,Juliana E. Hidalgo-Lopez,Srdan Verstovsek,Elias Jabbour,Farhad Ravandi,Gautam Borthakur,Zeev Estrov,Yesid Alvarado,Jan A. Burger,Heather Schneider,Kelly A. Soltysiak,Yue Wei,Hagop M. Kantarjian,Carlos E. Bueso-Ramos,Guillermo Garcia-Manero +14 more
TL;DR: Ruxolitinib was well-tolerated in previously treated lower-risk MDS patients with evidence of NF-kB activation and resulted in low but significant frequency of responses.